NR3C2 and chronic kidney disease: Another promising agent is finerenone, a non-steroidal selective mineralocorticoid receptor antagonist, which not only reduces CKD progression and cardiovascular events in patients with diabetic CKD but also demonstrates anti-inflammatory potential [194,195].